Cargando…
Nasal immune gene expression in response to azelastine and fluticasone propionate combination or monotherapy
BACKGROUND: The combination of the antihistamine azelastine (AZE) with the corticosteroid fluticasone propionate (FP) in a single spray, has been reported to be significantly more effective at reducing allergic rhinitis (AR) symptoms than treatment with either corticosteroid or antihistamine monothe...
Autores principales: | Watts, Annabelle M., West, Nicholas P., Smith, Peter K., Zhang, Ping, Cripps, Allan W., Cox, Amanda J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926499/ https://www.ncbi.nlm.nih.gov/pubmed/34813682 http://dx.doi.org/10.1002/iid3.571 |
Ejemplares similares
-
Quantitative proton nuclear magnetic resonance method for simultaneous analysis of fluticasone propionate and azelastine hydrochloride in nasal spray formulation
por: El-Masry, Amal A., et al.
Publicado: (2021) -
The Comparative Bioavailability of Fluticasone and Azelastine Delivered as a Single Fixed Dose Combination (MP-AzeFlu) in Comparison to Two Different Formulations of Azelastine and Fluticasone Propionate Following Intranasal Administration in Healthy Chinese Volunteers
por: Qi, Wenyuan, et al.
Publicado: (2023) -
Superior effect of MP-AzeFlu than azelastine or fluticasone propionate alone on reducing inflammatory markers
por: Roca-Ferrer, Jordi, et al.
Publicado: (2018) -
Superior effect of MP‐AzeFlu compared to monotherapy with fluticasone propionate or azelastine on GILZ, MKP‐1 and TTP anti‐inflammatory gene expression in healthy and inflamed upper airway mucosa
por: Vicens‐Artés, Sònia, et al.
Publicado: (2022) -
A Clinical Study to Assess the Efficacy and Safety of MP-AzeFlu Nasal Spray in Comparison to Commercially Available Azelastine Hydrochloride and Fluticasone Propionate Nasal Sprays in Chinese Volunteers with Allergic Rhinitis
por: Zhou, Bing, et al.
Publicado: (2023)